Class G refers to infliximab for injection, which is administered by intravenous infusion, with commonly recommended dosages of 3mg/kg, 5mg/kg, 10mg/kg, etc., depending on the disease. Infliximab for Injection is an anti-rheumatic drug. The use of this product is intravenous infusion, the drug dosage is more diverse, can not be generalized, need to be based on specific circumstances, there is obvious individual variability, mainly related to the original disease. Infliximab for injection can treat rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis and other diseases. For rheumatoid arthritis, the first dosage is 3mg/kg; for Crohn’s disease and ankylosing spondylitis, the first dosage is 5mg/kg, and if the first dosage does not have a good therapeutic effect, the doctor will consider adjusting the dosage to 10mg/kg. Secondly, some patients may experience adverse reactions such as chills, fever, chest pain, and so on, after using the drug. This drug is contraindicated in patients who are allergic to any of the components of this drug, in patients with tuberculosis and other active infections, and in patients with moderate to severe heart failure. This drug is a prescription drug, patients must cooperate with the doctor to regulate the application of Infliximab for Injection to avoid delays.